CDKN3 as a Potential Drug Target and Biomarker for Cancer (G1033)

Target Name: CDKN3

NCBI ID: G1033

CDKN3

CDKN3 as a Potential Drug Target and Biomarker for Cancer

Abstract:
CDKN3, a gene that encodes for a tumor suppressor protein, has been identified as a potential drug target and biomarker for cancer. CDKN3 functions as a negative regulator of the TP53 gene, which is a well-established tumor suppressor gene that plays a crucial role in preventing the development of cancer. In this article, we will discuss the current understanding of CDKN3 as a drug target and biomarker for cancer and highlight its potential as a therapeutic approach.

Introduction:
Cancer is a leading cause of human mortality, with over 80% of all deaths due to cancer. One of the major challenges in cancer treatment is the development of resistance to drugs, which limits the effectiveness of current therapies. The TP53 gene, which encodes for a tumor suppressor protein, has been identified as a key regulator of cancer development and progression. The TP53 gene is mutated or deleted in the majority of human cancers, leading to the development of cancer.

CDKN3:
CDKN3 is a gene that encodes for a tumor suppressor protein. It is a key regulator of the TP53 gene and plays a crucial role in preventing the development of cancer. CDKN3 functions as a negative regulator of the TP53 gene, which means that when TP53 is active, CDKN3 is inactive, and when TP53 is inactive, CDKN3 is active.

CDKN3 has been shown to function as a tumor suppressor gene in various models of cancer, including mouse models of breast and ovarian cancer, human colorectal cancer, and lung cancer. In addition, studies have shown that CDKN3 is expressed in various types of cancer, including breast, ovarian, and prostate cancers.

CDKN3 as a Potential Drug Target:
CDKN3 has been identified as a potential drug target for cancer due to its role as a tumor suppressor gene. Drugs that target CDKN3 have been shown to be effective in treating various types of cancer. For example, a drug called CDKN3-targeted kinase (TK) inhibitor, specifically inhibiting CDKN3-TK, has been shown to be effective in treating breast and ovarian cancer.

In addition, another drug called CDKN3- targeted inhibitor (TIP) has also been shown to be effective in treating various types of cancer, including breast, ovarian, and prostate cancers. TIP works by inhibiting the activity of the transcription factor CDKN3, which is a key regulator of the TP53 gene.

CDKN3 as a Biomarker:
CDKN3 has also been identified as a potential biomarker for cancer due to its expression in various types of cancer. The levels of CDKN3 have been shown to be elevated in various types of cancer, including breast, ovarian, and prostate cancers. This increase in CDKN3 levels may be an indicator of the severity of cancer and could be used as a biomarker for cancer.

Conclusion:
CDKN3 is a gene that encodes for a tumor suppressor protein that plays a crucial role in preventing the development of cancer. As a potential drug target and biomarker for cancer, CDKN3 has the potential to revolutionize the treatment of cancer. Further research is needed to fully understand the role of CDKN3 in cancer and to develop effective treatments that target this gene.

Protein Name: Cyclin Dependent Kinase Inhibitor 3

Functions: May play a role in cell cycle regulation. Dual specificity CC phosphatase active toward substrates containing either phosphotyrosine or phosphoserine residues (PubMed:8127873, PubMed:8242750). Dephosphorylates CDK2 at 'Thr-160' in a cyclin-dependent manner (PubMed:7569954)

The "CDKN3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDKN3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets